Elan veterans grab $34m for neurodegenerative diseases
This article was originally published in Scrip
Executive Summary
The only two employees at the virtual biotechnology company Annexon Biosciences are former Elan Pharmaceuticals business and research executives Doug Love and Ted Yednock, but they raised $34m in a Series A-1 venture capital funding round to advance drugs for neurodegenerative diseases.
You may also be interested in...
VC Roundup: Annexon, Mersana Benefit As Investors Favor Private Over Public Biotechs
During a month when only two biotechnology companies have gone public, private drug developers continue to raise hundreds of millions of dollars in venture capital.
Finance Watch: Perlmutter’s Eikon Raises $106m, In-Licenses Pipeline Programs
Private Company Edition: Former Merck R&D head Roger Perlmutter and his new team have accessed drug candidates in oncology and neurodegenerative diseases from three companies, along with new funding. Also, Carmot raised $150m in series E equity and BenchSci brought in $70m.
Eisai/Biogen’s Leqembi Gets Some Medicare Coverage Certainty In CMS Update
CMS said Medicare will cover anti-amyloid antibodies for early Alzheimer’s disease upon traditional approval from the US FDA if prescribed by doctors participating in a patient registry.